Humana Inc (NYSE:HUM) Director Sells $1,485,902.00 in Stock

Humana Inc (NYSE:HUM) Director David A. Jr/Ky Jones sold 5,800 shares of the business’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $256.19, for a total transaction of $1,485,902.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NYSE HUM traded up $19.63 on Tuesday, hitting $234.06. 3,403,243 shares of the stock were exchanged, compared to its average volume of 1,521,989. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.82 and a quick ratio of 1.82. The business’s fifty day moving average is $333.08 and its 200 day moving average is $323.14. Humana Inc has a 52 week low of $208.25 and a 52 week high of $384.99. The company has a market capitalization of $31.58 billion, a PE ratio of 11.66, a P/E/G ratio of 0.89 and a beta of 0.89.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 5th. The insurance provider reported $2.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.20 by $0.08. Humana had a net margin of 4.17% and a return on equity of 20.89%. The firm had revenue of $16.30 billion for the quarter, compared to analyst estimates of $16.15 billion. During the same period in the prior year, the firm posted $2.65 earnings per share. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. Analysts predict that Humana Inc will post 18.64 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.625 per share. This is a positive change from Humana’s previous quarterly dividend of $0.55. This represents a $2.50 annualized dividend and a yield of 1.07%. The ex-dividend date is Monday, March 30th. Humana’s dividend payout ratio is 12.31%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC raised its position in Humana by 9.7% during the fourth quarter. Quadrant Capital Group LLC now owns 2,430 shares of the insurance provider’s stock worth $874,000 after acquiring an additional 214 shares in the last quarter. Macquarie Group Ltd. raised its position in Humana by 8.1% during the fourth quarter. Macquarie Group Ltd. now owns 4,289 shares of the insurance provider’s stock worth $1,572,000 after acquiring an additional 322 shares in the last quarter. RMR Wealth Builders bought a new stake in Humana during the fourth quarter worth $1,602,000. Norges Bank bought a new stake in Humana during the fourth quarter worth $477,049,000. Finally, Osborn Williams & Donohoe LLC bought a new stake in Humana during the fourth quarter worth $234,000. 94.02% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently commented on HUM shares. JPMorgan Chase & Co. boosted their price objective on shares of Humana from $437.00 to $448.00 and gave the stock an “overweight” rating in a research report on Friday, January 3rd. Goldman Sachs Group reissued a “buy” rating and issued a $425.00 price objective on shares of Humana in a research report on Monday, January 27th. Morgan Stanley boosted their price objective on shares of Humana from $457.00 to $460.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Cantor Fitzgerald boosted their price objective on shares of Humana from $345.00 to $400.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $370.00 price objective on shares of Humana in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $384.00.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: Real Estate Investment Trust (REIT) ETF

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.